Profound Medical PROF
5.76
0.16
2.86%
as of 25 Sep
- Market cap
- $204.6M
- P/E
- 0.0×
Follow PROF
Growth Flags
show if company had growth for consecutive years
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (73.53%) | (70.59%) | (67.12%) | (124.49%) |
+8 more TTM periods Free account |
|
| (58.44%) | (57.92%) | (57.64%) | (93.08%) | ||
ROIC |
(137.78%) | (174.72%) | (230.01%) | (223.73%) | |
Return on Tangible Assets |
(65.09%) | (65.26%) | (60.20%) | (123.24%) | |
Average Days of Receivables |
183.86 | 182.81 | 163.25 | 208.48 | |
Free Cash Flow per Share |
(0.99) | (1.06) | (1.29) | (1.25) | |
Free Cash Flow |
(36.10) | (38.51) | (38.86) | (37.52) | |
Capital Expenditures |
— | — | (0.65) | — | |
Piotroski F-Score |
4.00 | 4.00 | 5.00 | 4.00 | |
| Other line items | |||||
Cash ROIC |
(38.99%) | (33.71%) | (29.24%) | (61.06%) | |
Accounts Receivable Turnover |
2.63 | 2.45 | 2.26 | 1.88 | |
Accounts Payable Turnover |
5.66 | 3.41 | 3.27 | 1.91 | |
Inventory Turnover |
0.57 | 0.69 | 0.67 | 0.53 | |
Average Days of Payables |
64.73 | 143.67 | 121.25 | 66.54 | |
Days of Inventory on Hand |
708.72 | 603.71 | 639.08 | 773.71 | |
Tax Rate |
0.01 | 0.01 | 0.01 | 0.00 | |
Research and Development Expense of Revenue |
107.96% | 111.88% | 127.94% | 146.70% | |
Selling, General and Administrative Expense of Revenue |
149.14% | 161.75% | 199.10% | 221.17% | |
Share Based Compensation of Revenue |
26.05% | 29.49% | 34.10% | 31.83% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
1.10 | 0.99 | 0.90 | 0.95 | |
Depreciation/Fixed assets |
0.88 | 0.73 | 0.80 | 2.04 | |
Capex/Depreciation |
0.00 | 0.00 | (1.17) | 0.00 | |
Revenue per Share |
0.53 | 0.52 | 0.53 | 0.47 | |
Operating CF per Share |
(0.99) | (1.06) | (1.26) | (1.25) | |
Capex per Share |
0.00 | 0.00 | (0.02) | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.04 | 0.00 | |
Net Profit Margin |
(171.56%) | (206.76%) | (264.44%) | (275.18%) |
Columns are period end dates